Are you Dr. Helman?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 94 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
7600 Shadywood Rd
Bethesda, MD 20817Phone+1 301-299-2922- Is this information wrong?
Summary
- Dr. Lee Helman, MD is an oncologist in Bethesda, Maryland. He is currently licensed to practice medicine in Maryland and California. He is affiliated with NIH Clinical Center.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1983 - 1986
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1980 - 1983
University of Maryland School of MedicineClass of 1980
Certifications & Licensure
MD State Medical License 1980 - 2024
CA State Medical License 2017 - 2021- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2003-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- Top Doctors:Baltimore Area Castle Connolly, 2012
- Join now to see all
Clinical Trials
- Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma Start of enrollment: 2002 Jun 01
- Blood and Tissue Study of Patients in NIH Protocol 08-C-0800 Start of enrollment: 2008 Dec 09
- Biomarkers in Tumor Tissue Samples From Younger Patients With Rhabdomyosarcoma Start of enrollment: 2011 Dec 01
Publications & Presentations
PubMed
- 143 citationsNew Horizons in the Treatment of Osteosarcoma.Lee J. Helman> ;The New England Journal of Medicine. 2021 Nov 25
- 7 citationsRecent Advances in Pediatric Cancer Research.Troy A. McEachron, Lee J. Helman> ;Cancer Research. 2021 Sep 24
- 2 citationsLRRC15 antibody-drug conjugates show promise as osteosarcoma therapeutics in preclinical studiesKatherine K. Slemmons, Sanjit Mukherjee, James W. Purcell, Lee J. Helman> ;Pediatric Blood & Cancer. 2021 Feb 1
- Join now to see all
Press Mentions
Stand up to Cancer Announces $3.25 Million in Grants for Research to Improve Treatment of Head and Neck CancersJanuary 21st, 2021- Mithramycin Induces Promoter Reprogramming and Differentiation of Rhabdoid TumorDecember 17th, 2020
- Chemical Genomics Reveals Histone Deacetylases Are Required for Core Regulatory TranscriptionJuly 8th, 2020
- Join now to see all
Grant Support
- Solid TumorsNational Cancer Institute2010–2011
- Molecular Biology Of Pediatric TumorsNational Cancer Institute2010–2011
- Solid TumorsDivision Of Clinical Sciences - Nci2009
- Molecular Biology Of Pediatric TumorsDivision Of Clinical Sciences - Nci2009
- Solid TumorsNational Cancer Institute2007–2008
- Molecular Biology Of Pediatric TumorsNational Cancer Institute2007–2008
- Molecular Biology Of Pediatric TumorsDivision Of Clinical Sciences - Nci1999–2006
- Solid TumorsDivision Of Clinical Sciences - Nci1996–2006
- Solid Tumors30Division Of Clinical Sciences - Nci2001
Professional Memberships
- Member
- Fellow
Hospital Affiliations
NIH Clinical CenterBethesda, Maryland
USC Norris Comprehensive Cancer CenterLos Angeles, California
